Vanguard Group Inc. raised its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 1.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,101,090 shares of the biotechnology company's stock after buying an additional 56,723 shares during the period. Vanguard Group Inc. owned about 9.10% of Repligen worth $734,251,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. Ballentine Partners LLC boosted its position in shares of Repligen by 4.0% during the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company's stock worth $270,000 after acquiring an additional 72 shares in the last quarter. CIBC Asset Management Inc increased its stake in shares of Repligen by 5.0% in the 4th quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock valued at $246,000 after purchasing an additional 81 shares during the last quarter. MML Investors Services LLC increased its stake in shares of Repligen by 2.7% in the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company's stock valued at $503,000 after purchasing an additional 89 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Repligen by 15.2% during the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company's stock worth $98,000 after buying an additional 90 shares during the last quarter. Finally, Louisiana State Employees Retirement System boosted its stake in Repligen by 0.7% in the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company's stock valued at $2,087,000 after buying an additional 100 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.
Repligen Trading Down 8.0 %
Repligen stock traded down $9.76 during mid-day trading on Friday, hitting $111.94. 1,826,070 shares of the stock were exchanged, compared to its average volume of 685,940. The stock has a market capitalization of $6.29 billion, a price-to-earnings ratio of -219.49, a PEG ratio of 4.54 and a beta of 0.95. Repligen Co. has a 12 month low of $107.30 and a 12 month high of $182.52. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The firm's fifty day simple moving average is $150.03 and its two-hundred day simple moving average is $147.51.
Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to analysts' expectations of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Analysts forecast that Repligen Co. will post 1.72 EPS for the current year.
Analyst Ratings Changes
A number of research analysts have recently commented on RGEN shares. Royal Bank of Canada increased their target price on shares of Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a report on Friday, February 21st. Evercore ISI began coverage on shares of Repligen in a research note on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $180.00 target price on shares of Repligen in a research note on Friday, February 21st. Canaccord Genuity Group raised their price objective on Repligen from $165.00 to $170.00 and gave the company a "hold" rating in a report on Friday, February 21st. Finally, JPMorgan Chase & Co. boosted their price objective on Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $178.64.
Get Our Latest Stock Analysis on Repligen
Insider Activity
In related news, Director Margaret Pax acquired 250 shares of the stock in a transaction dated Monday, March 17th. The stock was bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now directly owns 1,043 shares of the company's stock, valued at $157,169.67. The trade was a 31.53 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.20% of the stock is owned by company insiders.
About Repligen
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
See Also
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
